Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository

Recruiting Phase 1 Phase 2 Interventional Study
Malignancy Immune Related Adverse Events
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Sex
Any
Trial phase
Phase 1/2
Study type
Interventional
Purpose
Other
Participants needed
100 (estimated)
Sponsor
Brigham and Women's Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Immunotherapies have improved cancer outcomes, but have a unique profile of immune-related adverse events (irAEs). Biorepositories have been established to collect data and samples to help improve our understanding of irAEs, however identifying patients who are eligible for these biorepositories in a timely fashion can be challenging. The goal of this study is to determine if an informatics system…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Received or receiving a regimen containing one or more immuno-oncology therapeutics
Contacts

Danielle Bitterman, MD

617-632-5734

dbitterman@bwh.harvard.edu

CONTACT